PDL BioPharma, Inc. (PDLI) Tops Q3 EPS by 2c

PDL BioPharma, Inc. (NASDAQ: PDLI) reported Q3 EPS of $0.32, $0.02 better than the analyst estimate of $0.30. Revenue for the quarter came in at $85.2 million versus the consensus estimate of $85.03 million.

For earnings history and earnings-related data on PDL BioPharma, Inc. (PDLI) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• JPMorgan Upgrades Aviva Plc (AV/:LN) (AIVAF) to Overweight
• Capstone Energy+, Inc. (CEPL) Reports Q2 Loss of $0.03
• Hyperion DeFi (HYPD) Tops Q2 EPS by 57c